SG11202004662RA - Anti-c5 antibody combinations and uses thereof - Google Patents
Anti-c5 antibody combinations and uses thereofInfo
- Publication number
- SG11202004662RA SG11202004662RA SG11202004662RA SG11202004662RA SG11202004662RA SG 11202004662R A SG11202004662R A SG 11202004662RA SG 11202004662R A SG11202004662R A SG 11202004662RA SG 11202004662R A SG11202004662R A SG 11202004662RA SG 11202004662R A SG11202004662R A SG 11202004662RA
- Authority
- SG
- Singapore
- Prior art keywords
- antibody combinations
- antibody
- combinations
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/34—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762598023P | 2017-12-13 | 2017-12-13 | |
PCT/US2018/065123 WO2019118556A1 (en) | 2017-12-13 | 2018-12-12 | Anti-c5 antibody combinations and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202004662RA true SG11202004662RA (en) | 2020-06-29 |
Family
ID=65139108
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202004662RA SG11202004662RA (en) | 2017-12-13 | 2018-12-12 | Anti-c5 antibody combinations and uses thereof |
Country Status (13)
Country | Link |
---|---|
US (2) | US11365265B2 (en) |
EP (1) | EP3724226A1 (en) |
JP (2) | JP2021506241A (en) |
KR (1) | KR20200098528A (en) |
CN (1) | CN111630065A (en) |
AU (1) | AU2018383751A1 (en) |
CA (1) | CA3083113A1 (en) |
IL (1) | IL275264A (en) |
MA (1) | MA51147A (en) |
MX (1) | MX2020006113A (en) |
PH (1) | PH12020550825A1 (en) |
SG (1) | SG11202004662RA (en) |
WO (1) | WO2019118556A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10633434B2 (en) | 2016-06-14 | 2020-04-28 | Regeneron Pharmaceuticals, Inc. | Anti-C5 antibodies |
MA51147A (en) | 2017-12-13 | 2021-03-24 | Regeneron Pharma | ANTI-C5 ANTIBODY ASSOCIATIONS AND ASSOCIATED USES |
AU2019333047A1 (en) * | 2018-08-30 | 2020-12-03 | Regeneron Pharmaceuticals, Inc. | Methods for characterizing protein complexes |
EP4013784A1 (en) * | 2019-08-16 | 2022-06-22 | Regeneron Pharmaceuticals, Inc. | High concentration anti-c5 formulations |
JP2023548046A (en) * | 2020-10-23 | 2023-11-15 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | Method of treating patients with complement disorders using anti-C5 antibodies |
Family Cites Families (112)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4686100A (en) | 1985-04-02 | 1987-08-11 | The Board Of Trustees Of The Leland Stanford Junior University | Method for the treatment of adult respiratory distress syndrome |
ATE237682T1 (en) | 1991-07-15 | 2003-05-15 | Oklahoma Med Res Found | UNIVERSAL DONOR CELLS |
AU4657993A (en) | 1992-06-29 | 1994-01-24 | Alexion Pharmaceuticals, Inc. | Matrix for universal donor microvascular endothelial cells |
EP0751787B1 (en) | 1994-03-23 | 2005-01-12 | Alexion Pharmaceuticals, Inc. | Method for reducing immune and hemostatic dysfunctions during extracorporeal circulation |
US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
US5562904A (en) | 1994-07-21 | 1996-10-08 | Alexion Pharmaceuticals, Inc. | Retroviral transduction of cells using soluble complement inhibitors |
DE69534701T2 (en) | 1994-09-23 | 2006-10-19 | Alexion Pharmaceuticals, Inc., Cheshire | METHOD FOR THE TREATMENT OF INFLAMMATORY JOINT DISEASES |
US6673346B1 (en) | 1999-08-31 | 2004-01-06 | The Regents Of The University Of Michigan | Compositions and methods for the treatment of sepsis |
EP2281840A3 (en) | 2000-10-10 | 2012-05-23 | Genentech, Inc. | Inhibition of complement C5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
CA2457461C (en) | 2001-08-17 | 2013-12-24 | Tanox, Inc. | Complement pathway inhibitors binding to c5 and c5a without preventing the formation of c5b |
EP3372243A1 (en) | 2001-08-17 | 2018-09-12 | Genentech, Inc. | Complement pathway inhibitors binding to c5 and c5a without preventing formation of c5b |
ITMI20021527A1 (en) | 2002-07-11 | 2004-01-12 | Consiglio Nazionale Ricerche | C5 COMPONENT ANTIBODIES OF COMPLEMENT AND THEIR USE |
JP4601426B2 (en) | 2002-09-06 | 2010-12-22 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | Method for the treatment of asthma using antibodies against complement component C5 |
US9415102B2 (en) | 2002-09-06 | 2016-08-16 | Alexion Pharmaceuticals, Inc. | High concentration formulations of anti-C5 antibodies |
US20050271660A1 (en) | 2002-09-06 | 2005-12-08 | Alexion Pharmaceuticals, Inc. | Nebulization of monoclonal antibodies for treating pulmonary diseases |
US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
US7361339B2 (en) | 2003-01-09 | 2008-04-22 | Alexion Pharmaceuticals, Inc. | Methods for reducing morality associated with acute myocardial infarction |
EP1620544B1 (en) | 2003-04-17 | 2018-09-19 | Alnylam Pharmaceuticals Inc. | MODIFIED iRNA AGENTS |
ATE427356T1 (en) | 2003-06-02 | 2009-04-15 | Varleigh Ltd | COMPLEMENT INHIBITORS FROM TICKS |
US20070116710A1 (en) * | 2004-02-03 | 2007-05-24 | Leonard Bell | Methods of treating hemolytic anemia |
US20050169921A1 (en) | 2004-02-03 | 2005-08-04 | Leonard Bell | Method of treating hemolytic disease |
JP5848861B2 (en) | 2004-04-20 | 2016-01-27 | ジェンマブ エー/エスGenmab A/S | Human monoclonal antibody against CD20 |
EP2338511A3 (en) | 2004-05-14 | 2012-07-25 | Alexion Pharmaceuticals, Inc. | Prolongation of survival of an allograft by inhibiting complement activity |
US7763708B2 (en) | 2004-08-12 | 2010-07-27 | Institute For Protein Science Co., Ltd. | Methods and compositions for modulating C5-a-mediated inflammatory responses |
US8257740B1 (en) | 2011-08-15 | 2012-09-04 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
US8246995B2 (en) | 2005-05-10 | 2012-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells |
GB0518443D0 (en) | 2005-09-09 | 2005-10-19 | Evolutec Ltd | Method of treating myasthenia gravis |
US8883162B2 (en) * | 2005-10-19 | 2014-11-11 | Ibc Pharmaceuticals, Inc. | Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors |
AU2013200223B2 (en) | 2005-11-04 | 2015-08-20 | Genentech, Inc. | Use of Complement Pathway Inhibitors to Treat Ocular Diseases |
NZ567483A (en) | 2005-11-04 | 2012-04-27 | Genentech Inc | Use of complement pathway inhibitors to treat ocular diseases |
PL1988882T3 (en) | 2006-03-02 | 2015-04-30 | Alexion Pharma Inc | Prolongation of survival of an allograft by inhibiting complement activity |
IL302157A (en) | 2006-03-15 | 2023-06-01 | Alexion Pharma Inc | Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement |
WO2007143168A2 (en) | 2006-06-02 | 2007-12-13 | Regeneron Pharmaceuticals, Inc. | High affinity antibodies to human il-6 receptor |
PL2061810T3 (en) | 2006-09-05 | 2015-05-29 | Alexion Pharma Inc | Methods and compositions for the treatment of antibody mediated neuropathies |
PL2061501T3 (en) | 2006-09-08 | 2016-01-29 | Volution Immuno Pharmaceuticals Sa | Method of treating respiratory disorders |
GB0617734D0 (en) | 2006-09-08 | 2006-10-18 | Evolutec Ltd | Method of treating peripheral nerve disorders |
AU2007307375B2 (en) | 2006-10-10 | 2013-11-28 | Regenesance B.V. | Complement inhibition for improved nerve regeneration |
US8580735B2 (en) | 2007-02-05 | 2013-11-12 | Apellis Pharmaceuticals, Inc. | Local complement inhibition for treatment of complement-mediated disorders |
AR069130A1 (en) | 2007-11-02 | 2009-12-30 | Novartis Ag | LINK MOLECULES OF THE MAIN COMPLEMENT OPSONIN (C3B) AND METHODS TO MODULATE THE COMPLEMENT COMPONENT |
NZ623716A (en) | 2008-04-11 | 2016-04-29 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
AU2014201433B2 (en) | 2008-08-05 | 2016-05-26 | Novartis Ag | Compositions and methods for antibodies targeting complement protein C5 |
NZ600622A (en) | 2008-08-05 | 2013-12-20 | Novartis Ag | Compositions and methods for antibodies targeting complement protein c5 |
EP2340028B1 (en) | 2008-09-30 | 2018-06-27 | The Trustees Of The University Of Pennsylvania | Method of inhibiting biomaterial-induced procoagulant activity using complement inhibitors |
US9891219B2 (en) | 2008-10-10 | 2018-02-13 | Mayo Foundation For Medical Education And Research | Methods for treating neuromyelitis optica (NMO) by administration of eculizumab to an individual that is aquaporin-4 (AQP4)-IgG autoantibody positive |
HRP20230167T1 (en) | 2008-11-10 | 2023-03-31 | Alexion Pharmaceuticals, Inc. | Methods and compositions for treating complement-associated disorders |
JP2012531418A (en) * | 2009-06-23 | 2012-12-10 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | Bispecific antibodies that bind complement proteins |
KR102010827B1 (en) | 2009-06-26 | 2019-08-14 | 리제너론 파마슈티칼스 인코포레이티드 | Readily isolated bispecific antibodies with native immunoglobulin format |
CN102483501A (en) | 2009-07-17 | 2012-05-30 | 康宁光缆***有限责任公司 | Optical fiber ribbons and ribbon matrix materials having low oligomer content |
EP2327725A1 (en) | 2009-11-26 | 2011-06-01 | InflaRx GmbH | Anti-C5a binding moieties with high blocking activity |
WO2011083317A1 (en) | 2010-01-08 | 2011-07-14 | Varleigh Immuno Pharmaceuticals Limited | Ev576 for use in the treatment of viral infections of the respiratory tract |
AU2011213585B2 (en) | 2010-02-08 | 2014-02-06 | Regeneron Pharmaceuticals, Inc. | Common light chain mouse |
CA2791962A1 (en) | 2010-03-01 | 2011-09-09 | Alexion Pharmaceuticals, Inc. | Methods and compositions for treating degos' disease |
TWI667257B (en) | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | Antibodies with modified affinity to fcrn that promote antigen clearance |
ES2552954T3 (en) | 2010-04-30 | 2015-12-03 | Alexion Pharmaceuticals, Inc. | Anti-C5a antibodies and methods for the use of antibodies |
AU2015201676B2 (en) | 2010-04-30 | 2016-10-13 | Alexion Pharmaceuticals, Inc. | Anti-C5a antibodies and methods for using the antibodies |
CA2833785C (en) | 2011-04-21 | 2022-06-07 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for the treatment of neuromyelitis optica |
AU2012356170B2 (en) | 2011-12-21 | 2016-06-16 | Novartis Ag | Compositions and methods for antibodies targeting Factor P |
AU2013265255B2 (en) | 2012-05-25 | 2018-03-29 | Novartis Ag | Aqueous pharmaceutical composition containing a biologic therapeutic agent and guanidine or a guanidine derivative and an injection including the composition |
US9133269B2 (en) | 2012-08-24 | 2015-09-15 | Anaptysbio, Inc. | Humanized antibodies directed against complement protein C5 |
TW201418707A (en) * | 2012-09-21 | 2014-05-16 | Alexion Pharma Inc | Screening assays for complement component C5 antagonists |
CN105143261B (en) | 2013-01-31 | 2021-04-09 | 首尔大学校产学协力团 | C5 antibodies and methods for preventing and treating complement-associated diseases |
TWI635098B (en) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | Antibodies comprising chimeric constant domains |
CA2897334A1 (en) | 2013-03-29 | 2014-10-02 | Alexion Pharmaceuticals, Inc. | Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5 |
CN105683759B (en) | 2013-08-07 | 2019-03-29 | 瑞颂医药公司 | Atypia hemolytic uremic syndrome (aHUS) biomarker protein |
US10815296B2 (en) | 2013-09-16 | 2020-10-27 | Children's Hospital Medical Center | Methods of treatment of HSCT-associated thrombotic microangiopathy with eculizumab |
CA2926812A1 (en) | 2013-10-07 | 2015-04-16 | Massachusetts Eye And Ear Infirmary | Methods of preventing or reducing photoreceptor cell death |
US10238700B2 (en) | 2014-01-02 | 2019-03-26 | Genelux Corporation | Oncolytic virus adjunct therapy with agents that increase virus infectivity |
US20170073754A1 (en) | 2014-02-07 | 2017-03-16 | Novartis Ag | Impact of genetic factors on disease progression and response to anti-c5 antibody in geographic atrophy |
SG11201606842RA (en) | 2014-02-20 | 2016-09-29 | Allergan Inc | Complement component c5 antibodies |
BR112016017402A2 (en) | 2014-02-21 | 2017-10-17 | Medimmune Ltd | anti-pcsk9 ~ glp-1 fusions and methods for use |
NZ631007A (en) | 2014-03-07 | 2015-10-30 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
CA2940319A1 (en) | 2014-03-20 | 2015-09-24 | Inflarx Gmbh | Inhibitors of c5a for the treatment of viral pneumonia |
SG10202003996YA (en) | 2014-05-05 | 2020-06-29 | Regeneron Pharma | Humanized c5 and c3 animals |
US20170290876A1 (en) | 2014-06-25 | 2017-10-12 | Novartis Ag | Compositions and methods for long acting proteins |
US10177705B2 (en) | 2014-07-12 | 2019-01-08 | Kaneka Corporation | Composite solar cell, solar cell module, and concentrating solar cell |
WO2016094834A2 (en) | 2014-12-12 | 2016-06-16 | Alexion Pharmaceuticals, Inc. | A method for treating a complement mediated disorder caused by an infectious agent in a patient |
TWI617580B (en) | 2014-12-19 | 2018-03-11 | 中外製藥股份有限公司 | Anti-c5 antibodies and methods of use |
US20180016327A1 (en) | 2015-01-22 | 2018-01-18 | Chugai Seiyaku Kabushiki Kaisha | A Combination of Two or More Anti-C5 Antibodies and Methods of Use |
US20190135903A1 (en) | 2015-03-31 | 2019-05-09 | Alexion Pharmaceuticals, Inc. | Identifying and treating subpopulations of paroxysmal nocturnal hemoglobinuria (pnh) patients |
US20180311299A1 (en) | 2015-05-01 | 2018-11-01 | Alexion Pharmaceuticals, Inc. | Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of a kidney transplant |
US11840564B2 (en) | 2015-06-09 | 2023-12-12 | Children's Hospital Medical Center | Dosing algorithm for complement inhibitor |
US20160362482A1 (en) | 2015-06-10 | 2016-12-15 | Case Western Reserve University | Compositions and methods of modulating b cell response |
EP3307316A1 (en) | 2015-06-12 | 2018-04-18 | Alnylam Pharmaceuticals, Inc. | Complement component c5 irna compositions and methods of use thereof |
WO2017035362A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Use of complement pathway inhibitor compounds to mitigate adoptive t-cell therapy associated adverse immune responses |
WO2017044811A1 (en) | 2015-09-11 | 2017-03-16 | Bruce Andrien | Recombinant glycosylated eculizumab and eculizumab variants |
US20180237509A1 (en) | 2015-09-28 | 2018-08-23 | Alexion Pharmaceuticals, Inc. | Methods of treating adamts13 deficiencies and congenital thrombotic thrombocytopenia in pediatric patients |
US11203634B2 (en) | 2015-10-07 | 2021-12-21 | Alexion Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration in a patient comprising administering an anti-C5a antibody |
TW201718014A (en) | 2015-10-12 | 2017-06-01 | 諾華公司 | Use of C5 inhibitors in Transplant Associated Microangiopathy |
WO2017075325A1 (en) | 2015-10-30 | 2017-05-04 | Alexion Pharmaceuticals, Inc. | A method of inhibiting exacerbations of t cell-mediated allograft vasculopathy |
MX2018007144A (en) | 2015-12-18 | 2018-11-29 | Chugai Pharmaceutical Co Ltd | Anti-c5 antibodies and methods of use. |
EP3402816A1 (en) | 2016-01-11 | 2018-11-21 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment |
EP3408291A1 (en) | 2016-01-25 | 2018-12-05 | Shire Human Genetic Therapies, Inc. | Anti-c5 antibodies with enhanced ph switch |
GB201602802D0 (en) | 2016-02-17 | 2016-03-30 | Volution Immuno Pharmaceuticals Sa | Method of treatment |
CN109475630A (en) | 2016-05-27 | 2019-03-15 | 瑞颂医药公司 | The method for treating intractable Myasthenia |
EP3463460A1 (en) | 2016-06-07 | 2019-04-10 | Novartis AG | An anti-c5 antibody dosing regimen |
EP3464351A1 (en) | 2016-06-07 | 2019-04-10 | Novartis AG | Anti-c5 antibody for treating patients with complement c5 polymorphism |
US20190256845A1 (en) | 2016-06-10 | 2019-08-22 | Alnylam Pharmaceuticals, Inc. | COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) |
US10633434B2 (en) | 2016-06-14 | 2020-04-28 | Regeneron Pharmaceuticals, Inc. | Anti-C5 antibodies |
MX2018015030A (en) | 2016-06-17 | 2019-04-22 | Chugai Pharmaceutical Co Ltd | Anti-c5 antibodies and methods of use. |
US11303992B2 (en) | 2016-07-06 | 2022-04-12 | Macho Daisy, Llc. | Wearable device and system for personal audio messaging |
US20190256915A1 (en) | 2016-09-14 | 2019-08-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv | Methods of diagnosing and treating cd55 deficiency, hyperactivation of complement, angiopathic thrombosis and protein losing enteropathy (chaple), a newly identified orphan disease |
WO2018071624A1 (en) | 2016-10-12 | 2018-04-19 | Alexion Pharmaceuticals, Inc. | Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of a kidney transplant |
US10802945B2 (en) | 2016-12-07 | 2020-10-13 | Ab Initio Technology Llc | Differencing of executable dataflow graphs |
US20190330319A1 (en) | 2016-12-16 | 2019-10-31 | Samsung Bioepis Co., Ltd | Stable aqueous anti-c5 antibody composition |
TWI658834B (en) | 2017-01-31 | 2019-05-11 | 日商中外製藥股份有限公司 | A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease |
SG11201908238SA (en) | 2017-03-06 | 2019-10-30 | The Trustees Of The Univ Of Pensylvania | Anti-c5 antibodies and uses thereof |
SG11201908744PA (en) | 2017-03-23 | 2019-10-30 | Univ Pennsylvania | Anti-c5a antibodies and uses thereof |
US20200123238A1 (en) | 2017-04-19 | 2020-04-23 | Alexion Pharmaceuticals, Inc. | Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of a kidney transplant |
TWI786132B (en) | 2017-06-23 | 2022-12-11 | 德商因夫萊亞斯有限公司 | Activity |
MA51147A (en) | 2017-12-13 | 2021-03-24 | Regeneron Pharma | ANTI-C5 ANTIBODY ASSOCIATIONS AND ASSOCIATED USES |
-
2018
- 2018-12-12 MA MA051147A patent/MA51147A/en unknown
- 2018-12-12 JP JP2020531918A patent/JP2021506241A/en active Pending
- 2018-12-12 CA CA3083113A patent/CA3083113A1/en active Pending
- 2018-12-12 SG SG11202004662RA patent/SG11202004662RA/en unknown
- 2018-12-12 MX MX2020006113A patent/MX2020006113A/en unknown
- 2018-12-12 EP EP18836965.6A patent/EP3724226A1/en active Pending
- 2018-12-12 CN CN201880080737.5A patent/CN111630065A/en active Pending
- 2018-12-12 US US16/217,290 patent/US11365265B2/en active Active
- 2018-12-12 AU AU2018383751A patent/AU2018383751A1/en active Pending
- 2018-12-12 KR KR1020207017043A patent/KR20200098528A/en active Search and Examination
- 2018-12-12 WO PCT/US2018/065123 patent/WO2019118556A1/en unknown
-
2020
- 2020-06-03 PH PH12020550825A patent/PH12020550825A1/en unknown
- 2020-06-10 IL IL275264A patent/IL275264A/en unknown
-
2022
- 2022-05-17 US US17/663,675 patent/US20220275107A1/en active Pending
-
2023
- 2023-11-17 JP JP2023195577A patent/JP2024020446A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
MA51147A (en) | 2021-03-24 |
WO2019118556A1 (en) | 2019-06-20 |
IL275264A (en) | 2020-07-30 |
AU2018383751A1 (en) | 2020-06-25 |
MX2020006113A (en) | 2020-08-24 |
US20190177436A1 (en) | 2019-06-13 |
JP2024020446A (en) | 2024-02-14 |
CN111630065A (en) | 2020-09-04 |
EP3724226A1 (en) | 2020-10-21 |
JP2021506241A (en) | 2021-02-22 |
KR20200098528A (en) | 2020-08-20 |
US20220275107A1 (en) | 2022-09-01 |
PH12020550825A1 (en) | 2021-05-17 |
CA3083113A1 (en) | 2019-06-20 |
US11365265B2 (en) | 2022-06-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL263481A (en) | Anti-c5 antibodies and uses thereof | |
IL290842A (en) | Anti-cd73 antibodies and uses thereof | |
ZA202102905B (en) | Anti-galectin-9 antibodies and uses thereof | |
ZA202101318B (en) | Anti-phf-tau antibodies and uses thereof | |
IL268734A (en) | Anti-lag-3 antibodies and uses thereof | |
IL262095A (en) | Anti-pacap antibodies and uses thereof | |
IL269122A (en) | Anti-c5 antibodies and uses thereof | |
IL271477A (en) | Anti-cd166 antibodies and uses thereof | |
IL269134A (en) | Anti-par2 antibodies and uses thereof | |
IL265689A (en) | Anti-il-33 antibodies and uses thereof | |
IL275264A (en) | Anti-c5 antibody combinations and uses thereof | |
IL272476A (en) | Anti-apelin antibodies and uses thereof | |
IL273157A (en) | Axl-specific antibodies and uses thereof | |
IL271398A (en) | Anti-l1-cam antibodies and uses thereof | |
IL266049A (en) | Anti-o1 antibodies and uses thereof | |
IL266082A (en) | Anti-chikv antibodies and uses thereof | |
IL264417A (en) | Anti-o2 antibodies and uses thereof | |
GB201712032D0 (en) | Antibodies and uses thereof | |
IL274202A (en) | Anti-glyco-muc1 antibodies and their uses |